S&P 500   3,375.06 (+0.43%)
DOW   28,112.94 (+1.16%)
QQQ   268.72 (-0.59%)
AAPL   446.45 (-0.99%)
MSFT   205.62 (-1.26%)
FB   265.33 (+0.89%)
GOOGL   1,492.58 (-0.28%)
AMZN   3,132.56 (-0.50%)
NVDA   442.28 (-0.97%)
CGC   17.46 (-2.62%)
BABA   251.15 (+1.22%)
TSLA   1,396.85 (-1.53%)
GE   6.91 (+3.60%)
MU   48.98 (-0.35%)
AMD   79.94 (-2.80%)
T   30.62 (+1.39%)
F   7.33 (+3.39%)
ACB   10.05 (-1.66%)
GILD   68.71 (+0.29%)
NFLX   476.74 (-1.37%)
DIS   131.37 (+2.00%)
BAC   27.51 (+3.58%)
BA   187.86 (+4.70%)
S&P 500   3,375.06 (+0.43%)
DOW   28,112.94 (+1.16%)
QQQ   268.72 (-0.59%)
AAPL   446.45 (-0.99%)
MSFT   205.62 (-1.26%)
FB   265.33 (+0.89%)
GOOGL   1,492.58 (-0.28%)
AMZN   3,132.56 (-0.50%)
NVDA   442.28 (-0.97%)
CGC   17.46 (-2.62%)
BABA   251.15 (+1.22%)
TSLA   1,396.85 (-1.53%)
GE   6.91 (+3.60%)
MU   48.98 (-0.35%)
AMD   79.94 (-2.80%)
T   30.62 (+1.39%)
F   7.33 (+3.39%)
ACB   10.05 (-1.66%)
GILD   68.71 (+0.29%)
NFLX   476.74 (-1.37%)
DIS   131.37 (+2.00%)
BAC   27.51 (+3.58%)
BA   187.86 (+4.70%)
S&P 500   3,375.06 (+0.43%)
DOW   28,112.94 (+1.16%)
QQQ   268.72 (-0.59%)
AAPL   446.45 (-0.99%)
MSFT   205.62 (-1.26%)
FB   265.33 (+0.89%)
GOOGL   1,492.58 (-0.28%)
AMZN   3,132.56 (-0.50%)
NVDA   442.28 (-0.97%)
CGC   17.46 (-2.62%)
BABA   251.15 (+1.22%)
TSLA   1,396.85 (-1.53%)
GE   6.91 (+3.60%)
MU   48.98 (-0.35%)
AMD   79.94 (-2.80%)
T   30.62 (+1.39%)
F   7.33 (+3.39%)
ACB   10.05 (-1.66%)
GILD   68.71 (+0.29%)
NFLX   476.74 (-1.37%)
DIS   131.37 (+2.00%)
BAC   27.51 (+3.58%)
BA   187.86 (+4.70%)
S&P 500   3,375.06 (+0.43%)
DOW   28,112.94 (+1.16%)
QQQ   268.72 (-0.59%)
AAPL   446.45 (-0.99%)
MSFT   205.62 (-1.26%)
FB   265.33 (+0.89%)
GOOGL   1,492.58 (-0.28%)
AMZN   3,132.56 (-0.50%)
NVDA   442.28 (-0.97%)
CGC   17.46 (-2.62%)
BABA   251.15 (+1.22%)
TSLA   1,396.85 (-1.53%)
GE   6.91 (+3.60%)
MU   48.98 (-0.35%)
AMD   79.94 (-2.80%)
T   30.62 (+1.39%)
F   7.33 (+3.39%)
ACB   10.05 (-1.66%)
GILD   68.71 (+0.29%)
NFLX   476.74 (-1.37%)
DIS   131.37 (+2.00%)
BAC   27.51 (+3.58%)
BA   187.86 (+4.70%)
Log in

NASDAQ:UMRXUnum Therapeutics Stock Price, Forecast & News

$2.55
-0.09 (-3.41 %)
(As of 08/11/2020 11:10 AM ET)
Add
Compare
Today's Range
$2.47
Now: $2.55
$2.65
50-Day Range
$0.43
MA: $2.11
$3.32
52-Week Range
$0.29
Now: $2.55
$3.72
Volume16,471 shs
Average Volume962,505 shs
Market Capitalization$79.46 million
P/E RatioN/A
Dividend YieldN/A
Beta4.05
Unum Therapeutics Inc., a biopharmaceutical company, develops and commercializes immunotherapy products for cancer. The company is developing ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (r/r NHL). Its product portfolio also includes ACTR087 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r NHL; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; ACTR707 used in combination with trastuzumab that is in Phase I clinical trials for treating HER2+ solid tumor cancers; and BOXR1030, which is in pre-clinical stage, targets glypican-3 that improve T cell functionality in the solid tumor microenvironment. Unum Therapeutics Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
Unum Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:UMRX
CUSIPN/A
Phone617-945-5576

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.50 million
Book Value$1.04 per share

Profitability

Net Income$-31,830,000.00

Miscellaneous

Employees72
Market Cap$79.46 million
Next Earnings DateN/A
OptionableNot Optionable
$2.55
-0.09 (-3.41 %)
(As of 08/11/2020 11:10 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive UMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Unum Therapeutics (NASDAQ:UMRX) Frequently Asked Questions

How has Unum Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Unum Therapeutics' stock was trading at $0.3736 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, UMRX stock has increased by 582.5% and is now trading at $2.55.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Unum Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unum Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Unum Therapeutics
.

How were Unum Therapeutics' earnings last quarter?

Unum Therapeutics Inc (NASDAQ:UMRX) issued its earnings results on Monday, May, 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.30) by $0.10. The company earned $7.03 million during the quarter, compared to analysts' expectations of $3 million. Unum Therapeutics had a negative net margin of 99.09% and a negative return on equity of 83.39%.
View Unum Therapeutics' earnings history
.

What price target have analysts set for UMRX?

4 analysts have issued 12 month price objectives for Unum Therapeutics' shares. Their forecasts range from $3.00 to $4.00. On average, they expect Unum Therapeutics' stock price to reach $3.67 in the next twelve months. This suggests a possible upside of 43.8% from the stock's current price.
View analysts' price targets for Unum Therapeutics
.

What are Wall Street analysts saying about Unum Therapeutics stock?

Here are some recent quotes from research analysts about Unum Therapeutics stock:
  • 1. According to Zacks Investment Research, "Unum Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel immunotherapy products of immune system to cure cancer. The company's program consists of ACTR087 rituximab, ACTR707 RITUXIMAB, ACTR087 SEA-BCMA which are in clinical stage. Unum Therapeutics Inc. is based in Cambridge, United States. " (5/30/2020)
  • 2. HC Wainwright analysts commented, "Our price target of $18/share is based on an equally-weighted composite of: (a) $18.0/share, as a 25x multiple of taxed and diluted $7.63 discounted back to FY19 at 30% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $17.5/share (discounted cash flow analysis using a 18.0% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (8/13/2019)

Has Unum Therapeutics been receiving favorable news coverage?

Media coverage about UMRX stock has been trending neutral on Tuesday, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Unum Therapeutics earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Unum Therapeutics
.

Are investors shorting Unum Therapeutics?

Unum Therapeutics saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 1,980,000 shares, an increase of 375.4% from the June 30th total of 416,500 shares. Based on an average daily trading volume, of 2,750,000 shares, the short-interest ratio is presently 0.7 days. Approximately 10.1% of the shares of the company are short sold.
View Unum Therapeutics' Short Interest
.

Who are some of Unum Therapeutics' key competitors?

What other stocks do shareholders of Unum Therapeutics own?

Who are Unum Therapeutics' key executives?

Unum Therapeutics' management team includes the following people:
  • Dr. Charles Wilson, CEO, Pres & Director (Age 55, Pay $807.42k)
  • Mr. Matthew S. Osborne, Chief Financial Officer (Age 48, Pay $517.98k)
  • Dr. Dario Campana, Scientific Founder & Chair of Scientific Advisory Board
  • Mr. John L. Green C.A., C.P.A., Principal Accounting Officer (Age 40)
  • Mr. Larry Weiner, VP of Technical Operations

When did Unum Therapeutics IPO?

(UMRX) raised $75 million in an IPO on Thursday, March 29th 2018. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Morgan Stanley and Cowen acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

What is Unum Therapeutics' stock symbol?

Unum Therapeutics trades on the NASDAQ under the ticker symbol "UMRX."

How do I buy shares of Unum Therapeutics?

Shares of UMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Unum Therapeutics' stock price today?

One share of UMRX stock can currently be purchased for approximately $2.55.

How big of a company is Unum Therapeutics?

Unum Therapeutics has a market capitalization of $79.46 million and generates $22.50 million in revenue each year. The company earns $-31,830,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. Unum Therapeutics employs 72 workers across the globe.

What is Unum Therapeutics' official website?

The official website for Unum Therapeutics is www.unumrx.com.

How can I contact Unum Therapeutics?

Unum Therapeutics' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-945-5576 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.